BioLife Solutions, Inc. (BLFS)

Market Cap	1.04B
Revenue (ttm)	154.81M
Net Income (ttm)	-103.83M
Shares Out	42.77M
EPS (ttm)	-2.48
PE Ratio	n/a
Forward PE	625.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	266,115
Open	25.82
Previous Close	26.02
Day's Range	23.75 - 26.30
52-Week Range	10.40 - 29.92
Beta	1.81
Analysts	Buy
Price Target	31.62 (+29.43%)
Earnings Date	Feb 27, 2023

About BLFS

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line ...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Nov 22, 1989
• Employees: 432
• Stock Exchange: NASDAQ
• Ticker Symbol: BLFS

Analyst Forecast

According to 15 analysts, the average rating for BLFS stock is "Buy." The 12-month stock price forecast is $31.62, which is an increase of 29.43% from the latest price.

Price Target

$31.62

(29.43% upside)

Analyst Consensus: Buy